Schering-Plough Animal Health Corporation Announces FDA Approval of Banamine® for Use in Lactating Dairy Cattle

BANAMINE® becomes the only non-steroidal anti-inflammatory drug.
calendar icon 19 October 2004
clock icon 1 minute read

Schering-Plough Animal Health Corporation announced that the U.S. Food and Drug Administration (FDA) has approved BANAMINE® (flunixin meglumine) for controlling pyrexia (fever) associated with acute mastitis, pneumonia and endotoxemia, as well as controlling the inflammation in endotoxemia such as that caused by coliform mastitis.

BANAMINE® anti-inflamatory drug is the only non-steroidal anti-inflammatory drug approved for lactating dairy cattle. It is also used extensively to treat beef cattle suffering from respiratory disease. “BANAMINE® means comfort for cows, which can aid recovery and provide peace of mind for producers,” says Norman Stewart, DVM, MS, manager of Schering-Plough Animal Health technical service.

BANAMINE® benefits the dairy producer by confirming a 36-hour milk withdrawal period, which helps prevent unnecessary milk wastage. Milk taken during treatment and for 36 hours after the last treatment must not be used for food. Schering-Plough Animal Health Corporation is a leading manufacturer and marketer of biologicals, pharmaceuticals and specialty products for food and companion animals. It is the worldwide animal health business of Schering-Plough Corporation (NYSE: SGP) of Kenilworth, N.J., a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

Visit the Banamine website. News Desk

© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.